The anti-tumor drug "TQB2101 (ROR1 ADC)" developed by SINO BIOPHARM (01177) has obtained the implied approval for clinical trials from the NMPA.

SINO BIOPHARM(01177) announced that the group's independently developed "TQB2101 (ROR1 ADC)" has obtained the clinical trial implied license from the National Medical Products Administration (NMPA) in China, intended for the treatment of advanced malignant tumors. Preclinical research data show that TQB2101 exhibits anti-tumor activity in various ROR1-positive tumor models, and has good safety characteristics. This approved Phase I clinical trial will focus on evaluating its safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy in humans.